From: Mandibular involvement in SAPHO syndrome: a retrospective study
Variables | Mandibular involvement | p valueb | |
---|---|---|---|
+ (n = 26) | − (n = 604) | ||
Age (years), median (range) | 28 (5–65) | 40 (10–71) | < 0.001 |
Sex (males/females), n (%) | 10/16 (38.5/61.5) | 193/411 (32.0/68.0) | 0.522 |
Disease duration at baseline (years), median (IQR) | 2 (1–8) | 2 (0.6–5) | 0.011 |
Age at onset of symptoms (years), median (IQR) | 22 (14–27) | 37 (29–48) | < 0.001 |
Age at onset of oral symptoms (years), median (IQR) | 25 (15–28) | – | – |
Duration of diagnosis (years), median (IQR) | 2 (0.8–3.0) | 2 (0.7–4.7) | 0.291 |
Dental procedurea in 1 month before the onset of oral symptoms, n (%) | 10 (38.5) | – | – |
Affected region of the mandible | – | – | |
 Left side, n (%) | 7 (26.9) | – | – |
 Right side, n (%) | 10 (38.5) | – | – |
 Bilateral, n (%) | 9 (34.6) | – | – |
Oral symptoms | Â | Â | |
 Jaw pain, n (%) | 24 (92.3) | – | – |
 Swelling of the ipsilateral face, n (%) | 22 (84.6) | – | – |
 Limitation of mouth opening, n (%) | 20 (76.9) | – | – |
Skin manifestations, n (%) | 15 (57.7) | 531 (87.9) | < 0.001 |
PPP, n (%) | 8 (30.1) | 490 (81.8) | < 0.001 |
SA, n (%) | 7 (26.9) | 61 (10.1) | 0.024 |
VAS, median (IQR) | 5 (3–6) | 4 (3–6) | 0.311 |
Serum hs-CRP (mg/ml), median (IQR) | 6.41 (2.39–21.59) | 4.00 (1.95–9.03) | 0.641 |
ESR (mm/h), median (IQR) | 21 (14–31) | 14 (8–28) | 0.413 |
HLA-B27 positive, n (%) | 0 (0) | 27 (4.7) | 0.623 |